Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yae Hidaka"'
Autor:
Yae Hidaka, Shinsuke Nakamura, Anri Nishinaka, Yuichi Takajo, Satoshi Inamasu, Satoshi Yomoda, Masamitsu Shimazawa, Hideaki Hara
Publikováno v:
Biological and Pharmaceutical Bulletin. 46:473-481
Autor:
Yae Hidaka, Aika Kuriyama, Anri Nishinaka, Kei Takahashi, Seigo Nakaya, Takeshi Kubota, Shinsuke Nakamura, Masamitsu Shimazawa, Hideaki Hara
Publikováno v:
BPB Reports. 6:47-54
Autor:
Shinichiro Fuma, Yae Hidaka, Anri Nishinaka, Hiroto Yasuda, Kota Aoshima, Shinsuke Nakamura, Hideaki Hara, Masamitsu Shimazawa
Publikováno v:
Molecular Vision; 2023, Vol. 29, p188-196, 9p
Autor:
Shinsuke, Nakamura, Anri, Nishinaka, Yae, Hidaka, Masamitsu, Shimazawa, Leo, Thomas, Remko A, Bakker, Hideaki, Hara
Publikováno v:
Investigative Opthalmology & Visual Science. 63:14
Semaphorin 3A (Sema3A) is a promising therapeutic target for macular edema in age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion (RVO). Anti-vascular endothelial growth factors (anti-VEGFs) are the current standard of
Autor:
Takumi Yamamoto, Tomomi Masuda, Miruto Tanaka, Hideaki Hara, Anri Nishinaka, Yae Hidaka, Takahiko Imai, Shinsuke Nakamura, Masamitsu Shimazawa, Yuki Inoue
Publikováno v:
The FASEB Journal. 35
Anti-vascular endothelial growth factor (VEGF) therapies are now the first-line treatment for many ocular diseases, but some patients are non-responders to these therapies. The purpose of this study was to determine whether the level of adiponectin i